B
Bull
Bull · 25%SXTC
$2.24
Scenario price
$0.065
-0.027 (-41.28%)At close
Loading chart…
- High
- 0.070
- Open
- 0.065
- VWAP
- 0.07
- Volume
- 52.68M
- Mkt Cap
- 1.01M
- Low
- 0.063
- Amount
- 3.48M
- EV/EBITDA, TTM
- 0.00
China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang.
AI analysis of China SXT Pharmaceuticals Inc (SXTC)
SellGiven the current price of $0.07 and an RSI of 27.828 indicating oversold conditions, SXTC appears to be a risky investment. The stock has experienced a staggering 100% decline year-to-date, and the recent 1-for-150 reverse stock split has not stabilized the share price, which is currently well below the Nasdaq's minimum bid requirement of $1. The main risk is the company's negative earnings with a P/E ratio of -0.082626, reflecting ongoing financial struggles.
Valuation Metrics
The current forward P/E ratio for China SXT Pharmaceuticals Inc (SXTC) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for SXTC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
8.510-09NewsfilterChina SXT Pharmaceuticals Closes $12 Million Direct Offering
8.510-08PRnewswireChina SXT Pharmaceuticals Announces Direct Offering of 8 Million Shares
- 8.507-24Newsfilter
China SXT Pharmaceuticals Closes $9 Million Direct Offering
8.507-23seekingalphaChina SXT Pharmaceuticals Secures $9M Direct Offering
9.502-02BenzingaDarkIris Inc Reports 27.3% Revenue Growth, Shares Surge
SXTC FAQ — answered by Alphio AI
China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Given the current price of $0.07 and an RSI of 27.828 indicating oversold conditions, SXTC appears to be a risky investment. The stock has experienced a staggering 100% decline year-to-date, and the recent 1-for-150 reverse stock split has not stabilized the share price, which is currently well below the Nasdaq's minimum bid requirement of $1. The main risk is the company's negative earnings with a P/E ratio of -0.082626, reflecting ongoing financial struggles.
Community
More ↗
$GNPX October 2024 and October 2025. Two Octobers in a row produced strong rallies, and anyone who has followed GNPX closely would recognize that. In 2024 the month finished up about 522%...... The sample is two years, both moves were tied to a thin float, and the current float is even smaller than it was over the last two years, so it may be worth watching for a trade. For that reason, I mentioned GNPX as a potential $SXTC type mover. Let's see what this month brings.
Show more
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.